drugset / Trial / NCT05716516

STUDY02001740;22SCH740: Estradiol For ER+ Advanced Breast Cancer (ESTHER)

NCT05716516

Phase 2 Recruiting 36 enrolled Dartmouth-Hitchcock Medical Center
NaSingle-groupOpen-labelTreatment

Summary

Determine whether subjects harboring ESR1-mutant/amplified breast cancer have a higher rate of clinical benefit from 17b-estradiol therapy than subjects with ESR1-wild-type breast cancer

Timeline

Start
2023-05-04
Primary completion
2027-05
Completion
2027-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Estradiol Other / unclassified

Indications